Biocomposites, a medical device company that engineers, manufactures, and markets products for regenerating bone and managing infection in bone and soft tissue, has acquired Artoss, a specialist manufacturer of innovative bone graft substitutes for use in orthopaedics, spine, foot and ankle, and dentistry.

Artoss provides a range of bone graft substitute products that use its proprietary NanoBone technology – a combination of nanocrystalline hydroxyapatite and silica gel – to provide optimal bone formation with easy handling. The special structure of NanoBone activates the bone-forming forces of the body and leads to very rapid bone healing. In addition to Artoss’ lead product NanoBone SBX Putty, the company offers a wide-range of indication specific product variants that are all ready-to-use, directly from their applicators.

Located in Rostock, Germany, Artoss will continue to develop and manufacture innovative products, but will now be able to serve a greater number of surgeons and patients through access to Biocomposites’ established, global distribution network.

Michael Harris, chief executive officer of Biocomposites, said: “We are delighted to have completed this acquisition of Artoss. Adding the NanoBone range of products to our portfolio provides us with a new differentiated offering to help surgeons treat their patients and a platform from which to develop new ready-to-use products. Following on from our acquisitions of Subiton and Synimed last year, we have established ourselves as the go-to provider for surgeons requiring bone regeneration and/or managing infection in bone and soft tissue.”